DRG Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of NHL for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major markets.

DRG Epidemiology’s NHL forecast will answer the following questions:

  • Of all people diagnosed with NHL, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of NHL over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph of the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

DRG Epidemiology forecasts the following NHL subpopulations:

  • Diagnosed incident cases of NHL by histology (FL, DLBCL, MCL, CLL/SLL, T-NK-cell).
  • Diagnosed incident cases: DLBCL (de novo, de novo + transformed).
  • De novo DLBCL incident cases by molecular subtype.
  • Transformed incident cases (FL to DLBCLandCLL to DLBCL).
  • Diagnosed prevalent cases of NHL by histology (FL, DLBCL, MCL, CLL/SLL, T-NK-cell).
  • Drug-treatable populations (FL, DLBCL, MCL, CLL/SLL, T-NK-cell).
  • Drug-treated status (FL, DLBCL, MCL, CLL/SLL).

Note: Coverage may vary by country.

Table of contents

  • Mature Markets Non-Hodgkin's Lymphoma
    • Introduction
      • Key Findings
      • Overview
    • Epidemiology Data
    • Methods
      • Diagnosed Incident Cases
      • De Novo Incident Cases of DLBCL by Molecular Subtype
      • Transformed Incident Cases from FL to DLBCL
      • Transformed Incident Cases from CLL to DLBCL
      • Stage Distribution
      • Diagnosed Prevalent Cases
      • Drug-Treatable Population
      • Drug-Treated Population
      • Lifetime DALYs Gained
    • Reference Materials
      • Literature Review
      • Risk/Protective Factors
      • Bibliography

Author(s): Stephanie Niquita; Nicole Zhang, MPH

Stephanie Niquita works as an associate epidemiologist at Decision Resources Group. Stephanie holds a masters in public health specializing in epidemiology from TISS, Mumbai and a medical degree from Hubei University of Chinese Medicine, People’s Republic of China. She has been trained as a community physician and has also supervised and coordinated various governmental and non-governmental public health projects.

Nicole Zhang is an Epidemiologist at Decision Resources Group. She focuses on the epidemiology of oncology and cardiovascular disorders. She holds an from Tufts Medical School where she specialized in epidemiology and biostatistics. She also holds a in Chemistry and Statistics from Mount Holyoke College. Prior to joining Decision Resources, she worked as a research analyst at Massachusetts General Hospital where she independently managed data from food information survey conducted in Chelsea, MA. She has also worked at Massachusetts Department of Public Health where she conducted secondary research in the fields of gestational diabetes.


Related Reports

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Landscape & Forecast | Disease Landscape & Forecast

The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over th...

View Details

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape and Forecast | G7 | 2019

The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (

View Details

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Unmet Need | Detailed, Expanded Analysis: Relapsed or refractory DLBCL - (US-EU)

MARKET OUTLOOK Relapsed/refractory diffuse large B-cell lymphoma (R/R

View Details

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Current Treatment | Detailed, Expanded Analysis (US)

Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of hematological malignancies that can be broadly classified into indolent and aggre...

View Details